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14, and at age 28 she was told she had hepatitis although 
her hepatitis testing was negative. She has a history of 
psoriasis and vitiligo. Her family history is notable for liver 
disease of unknown etiology in her grandmother, 
gallbladder and thyroid disease in her mother, daughter 
with psoriasis, and son with type 1 diabetes mellitus. 
She rarely drinks alcohol. She has taken an occasional 
Aleve for arthritic pains but had not taken any NSAIDs in 
two years. She does not smoke cigarettes or use illicit 
drugs. She worked at a large wholesale grocery as a 
door greeter.
Her physical exam was notable for prominent scleral 
icterus, diffuse jaundice, abdominal distension with 
dullness in flanks but no tenderness, 3+ pitting edema in 
bilateral lower extremities, chronic vitiligo of hands and 
chest, palmar erythema, asterixis with mild confusion, 
but no spider angiomas or malar rash.
Her labs were significant for iron overload with iron 
saturation of 95%, elevated ferritin of 4400 ng/mL, 
decreased transferrin to 138 mcg/dL, and iron level 
elevated to 185 mcg/dL. She had a macrocytic anemia 
with hemoglobin of 9.0 g/dL, MCV 108 and normal B12 
and folate. 
Labs were negative for CMV, EBV, VZV, HAVAb, HBGAg, 
HBVAb, HCVAb, and HIV. Normal AFP (3.7 ng.mL), A1AT 
(14 mg/dL), TSH (3.4 uIU/mL), A1c 4.1, and low normal 
ceruloplasmin (19mg/dL). Presenting MELD-Na score 
was 17 (Cr 0.6, Bili 4.9, INR 1.5, Na 140). 
Elevated IgG, but negative ANA and ASMA (ruling out AIH 
and PBC). Gene mutations for primary HFE (C282Y and 
H63D) were negative.
MRI (Figure 1) was consistent with primary hemochro-
matosis effecting the non-reticuloendothelial system 
(non-RES); involving the liver, but not the spleen or bone 
marrow. Additionally, on the dual-sequence MRI 
(Figure 2) there is a drop in signal intensity on the image 
with the longer echo time10.
Liver biopsy (Figure 3) demonstrated bridging fibrosis 
and focal nodularity, stage 3-4. Features of chronic 
hepatitis evidenced by mild lobular and portal 
inflammation. Iron stain showing 4+ hepatocellular iron 
deposit. No evidence of steatohepatitis. No evidence of 
portal edema or brisk ductular reaction to support biliary 
obstruction.
Despite treatment her condition progressed to ESLD and 
she was listed with successful liver transplantation.
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ABSTRACT
Non-HFE hemochromatosis is a rare cause of end stage 
liver dysfunction that is characterized by excessive iron 
deposition in the liver. The vast majority of primary iron 
overload is due to well documented mutations of the 
HFE genetic locus, however, rare genetic cases not 
involving the HFE locus have been documented. Here 
we present the case of a 63-year-old female who 
developed liver failure due to non-HFE hemochro-
matosis. Secondary causes of iron overload were ruled 
out, and genetic testing was negative for primary HFE 
(C282Y and H63D) mutations. We discuss the clinical 
work up involved in making the diagnosis of non-HFE 
hemochromatosis and the treatment options.
Keywords: Non-HFE Hemochromatosis, primary 
hemochromatosis, iron overload, hereditary hemochro-
matosis
INTRODUCTION  
Hereditary Hemochromatosis (HH) is a disease 
characterized by increased intestinal absorption of iron 
and subsequent deposition in tissues. Hemochromatosis 
is a progressive disease that without therapeutic 
intervention can lead to iron accumulation in tissues 
leading to organ damage such as liver cirrhosis, diabetes, 
skin discoloration, and cardiomyopathy1. 
Primary hemochromatosis due to the HFE gene is the 
most common identified genetic disorder in Caucasians 
of northern European descent with a prevalence of 1 in 
200 individuals and accounting for 60-95% of European 
iron overload cases2. In contrast, most cases of iron 
overload that do not involve the HFE gene are due to 
secondary hemosiderosis. However, there are rarely 
observed gene mutations that result in primary 
hemochromatosis collectively called non-HFE 
hemochromatosis3.
CASE REPORT
A 63-year-old Caucasian female presented for evaluation 
of abnormal bile duct appearance on ERCP after being 
diagnosed with gallstone pancreatitis, duodenal ulcers 
and gastritis at another hospital. Over the past several 
years she had noticed increasing fatigue, unintentional 
weight gain of 30 pounds, lower extremity and abdominal 
swelling. The patient recalls having jaundice at the age of 
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DISCUSSION  
Hereditary Hemochromatosis (HH) is a disease of iron 
overload that is most commonly due to mutations of the 
HFE gene. The HFE gene mutation most commonly 
involves a tyrosine for cysteine substitution at amino acid 
position 282, or protein product C282Y1. The allele 
frequency of C282Y is close to 5% in European 
populations according to the 1000 Genomes Project 
and explains the large number of European persons with 
primary hemochromatosis who are homozygous for 
C282Y HFE gene2. 
Rarely, there are cases of iron overload consistent with 
primary hemochromatosis that do not involve the HFE 
gene collectively called non-HFE hemochromatosis3. 
These non-HFE genes include hemojuvelin (HJV), 
hepcidin (HAMP), transferrin receptor (TFR2) and 
ferroportin (SLC40A1). Though most known forms of 
primary hemochromatosis have recessive inheritance, 
SLC40A1 is recognized as a rare autosomal dominant 
inherited genotype that can be associated with a splicing 
mutation4. These gene mutations have phenotypes that 
range from the severe juvenile forms of iron overload as 
in mutations of HJV and HAMP to the milder phenotypes 
associated with TFR2 and SLC40A15. Typically, the earlier 
onset forms involve severe endocrine and cardiac 
manifestations that can result in death by the age of 305. 
Notably, ferroportin mutations were first described in 
1999 in individuals of Italian and Dutch descent, but 
were later observed in gene sequencing of Asian, 
American and African populations6,7. 
The diagnosis of non-HFE hemochromatosis involves 
ruling out secondary causes of iron overload, quantifying 
liver iron stores via MRI or liver biopsy, determine the 
hereditary nature of the iron overload by genetic testing 
(typically for HFE only)8. As mentioned previously, MRI 
did not show involvement of spleen or bone marrow 
whereas for hemosiderosis or secondary hemochro-
matosis, iron deposition would be prominent in these 
locations.
Estimates of the prevalence of non-HFE hemochromatosis 
were previously about 10%6. To date, 55 HJV cases, 13 
HAMP cases, 49 TFR2 cases, and 60 cases of SLC40A1 
disease have been reported7. Next-generation sequencing 
supports the rarity of these non-HFE pathogenic alleles 
with predicted frequencies ranging from 0.00007 to 
0.0004. Compare this to the 5% allele frequency of the 
C282Y missense substitution as previously noted. 
Corresponding predicted frequencies of the genotypes 
range from 1 in 556 for SLC40A1 to 1 in 6,000,000 for 
TFR2 and as rare as 1 in 181,000,000 for HAMP7.
Heterozygous mutations in SLC40A1 lead to ferroportin 
disease and we were surprised to find relatively high 
frequencies of SLC40A1 variants classified as pathogenic. 
These variants were found at the highest frequencies 
among African populations (0.25%) but were also present 
in the American (0.039%), East Asian (0.033%), and 
non-Finnish European (0.03%) populations7. Non-HFE 
HH seems to be more prevalent in southern Europe 
compared with northern Europe.
Due to the lack of widely available direct gene 
sequencing, these non-HFE genes are not recommended 
to be tested unless investigating severe refractory cases8.
Figure 1: Figure 1: T2 weighted MRI showing decreased enhancement of the liver 
(darker appearance) but not the spleen, characteristic in iron overload due to primary 
hemochromatosis. 
Figure 2: Dual sequence MRI “In Phase and Out of Phase” showing decreased signal 
of the liver on the “In Phase” image (left) compared to “Out of phase” image (right) 
which is consistent with hemochromatosis. The iron deposition is more severe 
in the liver.
Figure 3: Iron stain from our patient showing 4+ hepatocellular iron deposition (left 
blue stain). H&E stain demonstrated bridging fibrosis and focal nodularity, stage 3-4 
(right pink stain) Features of chronic hepatitis evidenced by mild lobular and portal 
inflammation. 
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